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Several protocols are actually available for in Vitro Fertilization and Embryo Transfer. The review summarizes the
main differences and the clinic characteristics of the protocols in use with GnRH agonists and GnRH antagonists by
emphasizing the major outcomes and hormonal changes associated with each protocol. The majority of
randomized clinical trials clearly shows that in “in Vitro” Fertilization and Embryo Transfer, the combination of
exogenous Gonadotropin plus a Gonadotropin Releasing Hormone (GnRH) agonist, which is able to suppress
pituitary FSH and LH secretion, is associated with increased pregnancy rate as compared with the use of
gonadotropins without a GnRH agonist. Protocols with GnRH antagonists are effective in preventing a premature
rise of LH and induce a shorter and more cost-effective ovarian stimulation compared to the long agonist protocol.
However, a different synchronization of follicular recruitment and growth occurs with GnRH agonists than with
GnRH antagonists. Future developments have to be focused on timing of the administration of GnRH antagonists,
by giving a great attention to new strategies of stimulation in patients in which radio-chemotherapy cycles are
needed.
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Several randomized clinical trials demonstrate that in
IVF-ET, the combination of exogenous gonadotropin plus
Gonadotropin Releasing Hormone agonist (GnRH-a), for
the suppression of pituitary FSH and LH secretion, is
associated with higher pregnancy rates as compared to the
use of gonadotropins without GnRH-a. The major benefits
of these drugs include decreased cancellation rate through
prevention of premature LH surge and luteinisation [1],
enhancement of follicular recruitment, allowing the recov-
ery of a larger number of oocytes [2], and the improve-
ment in routine patient treatment schedule [3]. The gold
standard for ovarian stimulation in young normo-
gonadotropic women is recognized as the long protocol,
starting GnRH-a in the mid luteal phase of the preceding
cycle (Figure 1). A systematic overview of twenty-six trials
comparing different GnRH-a protocols for pituitary* Correspondence: ilariatotaro.it@libero.it
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reproduction in any medium, provided the ordesensitization in in vitro fertilization demonstrated the
superiority of the long protocol over the short and ultra-
short protocols (OR 1.32 for clinical pregnancy rate per
cycle started), with GnRH analogue being commenced ei-
ther in follicular phase or in luteal phase [4]. GnRH-a long
protocol, induces profound suppression of endogenous re-
lease of gonadotropins during the early follicular phase,
allowing the early antral follicles to grow co-ordinately in
response to exogenous gonadotropins to accomplish sim-
ultaneous maturation. This leads to an extended widening
of the FSH window, an increased number of recruited ma-
ture follicles and a higher number of retrieved oocytes [4].
Two types of GnRH-a administration pattern can be
used to lead to pituitary desensitization in the long
protocol; one consisting of low dose (0.1 mg) of GnRH-a
daily and another consisting of the administration of
higher doses (3.75 mg, depot) of long-acting analogues.
Albuquerque et al. [5], in a meta-analysis of six rando-
mized controlled trials (RCTs), found that pregnancy
rates are similar in the long protocol using depot or
daily GnRH analogues. However, the use of long-acting
analogues is associated with an increasing requirementLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 GnRH agonist protocols. Long Protocol: GnRH agonist 0.1 mg starting in follicular phase or luteal phase (Cycle Day 21) of the previuos
cycle until hCG administration . Short Protocol: GnRH agonist 0.1 mg starting on day 1 or 3 of stimulation until hCG administration. Ultrashort
Protocol: GnRH agonist 0.1 mg administered on day 2–4 of stimulation.
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tion compared to the daily GnRH-a low dose. In patients
with normal BMI compared to over-weight patients, it
was demonstrated that low doses of tryptorelin
(0.05 mg, daily) are adequate to prevent a premature LH
rise, resulting in reduced gonadotropin levels and
increased clinical outcomes[6]. Since GnRH receptors
are expressed in human ovary, it was suggested that high
doses of GnRH-a may induce desensitization of ovarian
receptors in normal or underweight patients. In contrast,
in overweight women, increased fat mass may account
for either increased steroid storage or increased periph-
eral conversion of androgens to estradiol (E2), thus pro-
viding a source for serum E2 levels when ovarian
steroidogenesis might be suppressed [6].
The use of GnRH agonists in the long protocol is char-
acterized by some disadvantages for the patients: a) the
drawback of a long treatment period until desensitization
occurs [7]; b) the increased risk of the ovarian hyperstimu-
lation syndrome (OHSS) [8]; c) more frequent occurrence
of side effects (e.g., hot flushes, headache, bleeding, and
cyst development) during the desensitization period [9,10].
The introduction of GnRH antagonists (GnRH-ant) in
Assisted Reproductive Technologies (ART) to prevent
LH surge, seemed to open up a new way towards a more
“friendly IVF” [11]. Unlike the indirect pituitary suppres-
sion induced by GnRH-a, GnRH-ant administration
causes immediate and dose-related inhibition of gonado-
tropins release by competitive occupancy of the GnRH
receptors in the pituitary [12].
The use of GnRH-ant leads to a significant reduction in
the duration of ovarian stimulation. GnRH antagonists are
also not associated with acute induction of gonadotropins,
which may induce cyst formation. In addition, no hot
flushes are observed with GnRH-ant because their use
does not result in the profound hypo-oestrogenemia
observed with GnRH-a. Finally, a reduced incidence ofmoderate and severe OHSS may occur while using
GnRH-ant. In a Cochrane review, Al-Inany et al. have
shown that women receiving antagonists, have a signifi-
cantly lower incidence of OHSS when treated with GnRh
ant compared with women treated with GnRh agonist
(RD=− 0.03, 95% CI=− 0.05 to 0.02, P< 0.00001) [13]
In a meta-analysis comparing GnRH-a versus GnRH-
ant for controlled ovarian stimulation in oocyte donors,
Bodri et al. found no significant difference in the inci-
dence of OHSS by comparing protocols with GnRH ago-
nists versus antagonists[RR 0.61(95%) CI 0.18 to 2.15,
P = 45, heterogeneity P = 45, I2 0% fixed effects model]
[14]. Moreover, the GnRh antagonist protocol makes it
possible to trigger ovulation with GnRh agonist instead
of hCG, minimizing the risk of OHSS and securing the
appropriate maturation of oocytes.
In a recent review, it has been demonstrated that in
fresh IVF cycles with ET, no OHSS was reported after
GnRH ant [risk difference of 5% when compared with
GnRH a group (with 95% CI: -0.07 to 0.02)][15].
Ovulation triggering with GnRH agonist, in GnRH ant
protocols is associated with the strategy to freeze all
oocytes for future use, and this could be the tool to-
wards eradication of OHSS[16]. (Written informed con-
sent was obtained from the patient for publication of
this report).
The above considerations are corroborated by recent
reports indicating a classic GnRh-ant protocol where
ovulation induction is carried out with GnRh agonist,
associated with decreased risk of post-trigger oestradiol
exposure as well as OHSS risk in women with breast
cancer [17-19].
In our experience, the avoidance of an acute stimula-
tion of endogenous gonadotropins, the short duration of
treatment, and the ability to inhibit directly the prema-
ture LH surge made GnRH-ant the most appropriate
regimen for ovarian stimulation, for embryo or gamete
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Two GnRH-ant regimens have been developed for con-
trolled ovarian stimulation, involving either single admin-
istration [20] or multiple administrations [21]. (Figure 2).
In the single dose protocol, the administration of a 3 mg
dose of GnRH-ant on day 7 of the ovarian stimulation was
shown to prevent a premature LH surge [22]. In the mul-
tiple dose protocol, the GnRH-ant was administered con-
tinuously until the day of hCG, and the minimal effective
dose to prevent the occurrence of a premature LH rise
was identified as 0.25 mg of Cetrorelix [23,24]. No signifi-
cant difference in pregnancy rates was shown in a rando-
mized controlled trial which compared single injections of
cetrorelix acetate (3 mg) and a daily dose of ganirelix
(0.25 mg) in the inhibition of premature LH surge. How-
ever, the single-dose GnRH-ant protocol has the advan-
tage to reduce the number of injections, although
additional daily doses of antagonist are needed in 10% of
cycles [25]. Moreover, in some cases a 3 mg-dose may re-
sult in excessive and potentially harmful suppression of
endogenous LH [26].
Fixed versus flexible regimen: Which is the most effective?
Defining the most appropriate time to start cetrorelix
administration has been the subject of several studies.
From the physiological point of view, GnRH-ant admin-
istration should start when there is follicular develop-
ment and/or production of E2 by the developing follicles
which may cause a premature elevation in pituitary LH
release, due to positive feedback mechanisms.
The most common type of treatment called fixed proto-
col consists of giving GnRH-ant 5 days after the stimula-
tion with gonadotropins. However, in order to reduce theFigure 2 GnRH antagonist protocols. Fixed day 6 protocol: 0.25 mg GnR
[23]. Single dose protocol. 3 mg GnRH antagonist at day 7 of stimulation (O
antagonist when follicles reach >14 mm (Diedrich et al., HR 1994) [21].number of antagonist injections and the duration of
stimulation, the flexible protocol was introduced. It con-
sists in administering GnRH antagonist when the follicles
reach a size of >14 mm [27,28].
A meta-analysis by Al Inany [29] evaluated four RCTs
[27,28,30,31] that were performed to compare fixed versus
flexible GnRH-ant protocols. There was no significant stat-
istical difference in pregnancy rate per randomized woman
(OR=0.7 95% CI=0.47 to 1.05), and no significant differ-
ence in the incidence of premature LH surge in both
protocols.
Several studies have raised concerns regarding an un-
favourable effect of late administration of GnRH-ant, either
on day 6 of stimulation or later in flexible protocols. With
this mode of administration, LH levels remain unsup-
pressed during the early follicular phase and enhance E2
production. In the flexible protocol, high exposure of the
genital tract to LH, E2 and progesterone levels during the
early follicular phase, might adversely affect the implant-
ation rate mainly by altering endometrial receptivity, lead-
ing to a worse reproductive outcome. Kolibianakis et al.,
[32], in a randomized controlled trial, showed that starting
the GnRH-ant either on stimulation day 1 or on stimula-
tion day 6 resulted in equal follicular development. In
addition, its use was suggested in Polycystic Ovarian Syn-
drome patients with high LH levels, during the follicular
phase.
When analyzing follicular development and endocrine
profile of patients who received their first GnRH- ant
administration on day 8 or later, it was noticed that
these patients had a higher number of follicles> 11 and
<15 mm in diameter and high E2 and LH levels com-
pared to patients in the fixed protocol group. This data
suggests that in this flexible regimen, the cohort ofH antagonist/daily until hCG administration (Albano et al.,F&S 1997)
livennes et al.,HR 1998) [22]. Flexible dose protocol: 0.25 mg GnRH
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number of follicles in mid-follicular phase [28]
The optimal levels of endogenous LH in GnRH-ant
cycles, are still a matter of debate. It may be assumed that
the deep suppression of LH secretion induced by GnRH-a
administration is likely to be detrimental for the follicle-
oocyte complex. A low residual LH concentrations and
impaired E2 secretion with increasing doses of antagonist
were indeed associated with low implantation rates [24].
On the other hand, a trend towards lower pregnancy rates,
was observed in patients with LH deficiency, documented
by low E2:oocyte ratio, which could be explained by the
endometrial impact of low LH levels [33]. On the basis of
these observations, the possibility of LH supplementation
in GnRH-ant regimens was examined. Data from two ran-
domized controlled trials showed that the addition of
75 IU of recombinant LH to recombinant FSH at GnRH-
ant initiation, or from initiation of stimulation, does not
appear to increase pregnancy rates [34]. Similarly, no im-
provement in pregnancy rates could be shown by increas-
ing the dose of HMG by 75 IU at GnRH-ant initiation
[35]. Both studies show no evidence, that low endogenous
LH levels after GnRH-ant initiation are associated with a
decreased probability of pregnancy in IVF cycles [31,36].
In a third study of Baruffi et al., a meta analysis of five
RCT, significantly higher serum E2 concentration and
number of MII oocytes were observed in GnRh ant cycle
supplemented with LH, suggesting that LH may prevent
any decrease in oestradiol levels after antagonist adminis-
tration even if there was no significant difference in im-
plantation and pregnancy rates [37]. It was suggested that
lower the LH levels on day 8 of stimulation for IVF, higher
was the probability of pregnancy [32]. High serum LH
levels at early stage of stimulation might be responsible
for advanced endometrial maturation which induces an
early closure of the implantation window through earlier
expression of progesterone receptors in the follicular
phase and downregulation of E2 receptors by the exposure
to supraphysiological steroid hormone levels [30].
Huirne et al. highlighted the evidence that during
GnRH-ant administration, very large changes (either in-
crease or decrease) in LH levels, rather than absolute
LH levels, are associated with a decreased chance of
clinical pregnancy [38].
The use of oral contraceptive pill (OCP) has been con-
sidered as a mean for programming IVF cycles using
GnRH-ant [33], and it has been speculated that the use of
OCP pre-treatment may result in improved synchron-
ization of the recruitable cohort of ovarian follicles. A
study by Kolibianakis et al.[39] showed no significant effect
of OCP pre-treatment on the probability of pregnancy in
GnRH-ant cycles; however easier scheduling of the cycle,
an increase of gonadotropin requirement, and a longer
duration of treatment was observed with the use of OCP.However in a recent meta-analysis, encompassing 1343
randomized patients, Griesinger et al. (2010) observed that
the probability of an ongoing pregnancy per randomized
woman was found to be significantly lower in patients
who received OC pre-treatment. (RR 0.80, 95% CI : 0.66
to 0.97, P = 0.02) [40]
Finally the potential beneficial effect of GnRH-ant on
pregnancy rate in intrauterine insemination(IUI) cycles,
has been assessed in a recent meta-analysis conducted by
Kosmas on six studies with 521 women [41]. Higher preg-
nancy rates were found (16.9% in the antagonist group
and 11.5% in the control group) when GnRH-ant was
administered. Moreover a trend for multiple pregnancies
was also observed when GnRH-ant was administered.
Increased duration for administration of gonadotropins
was observed in the GnRH-ant group compared with the
control-group.
GnRH-a versus GnRH-ant regimens
Several RCTs have been designed to compare the effi-
cacy of the GnRH-ant with that of GnRH-a long proto-
col, but these studies often show conflicting results.
Significantly less gonadotropin ampoule consumption
and stimulation days in GnRH-ant regimes with respect
to GnRH-a regimen [28,42] was observed. No significant
difference was observed in the clinical pregnancy rates
and the live birth rates between the two different regi-
mens [28]. Although a similar number of good embryos
were obtained and replaced in both groups, the implant-
ation rate and clinical and ongoing pregnancy rates
tended to be lower in GnRH-ant group. The miscarriage
rate however was comparable [42]. Moreover, a lower
mean number of cumulus-oocyte-complexes (COC) and
2 pronuclear (PN) oocytes were found in GnRH-ant
group than in GnRH-a group [28,42].
LH and E2 concentrations, in early follicular phase,
were higher in GnRH-ant regime as compared with
GnRH-a regime, whereas the LH concentrations on the
day of hCG were comparable in both protocols [42]. A
premature LH rise was observed in 4.3% of GnRH-ant
patients [28] and in 3% of GnRH-a patients [42]. OHSS
grade II and III (WHO classification) was significantly
higher in GnRH-a group (1.1% P = 0.03) and finally, the
initiation of FSH administration in a GnRH-ant regimen
was found to be cycle-dependent, making treatment
planning and scheduling more difficult [38,43].
Now that more than 200 papers have been published
with the aim to compare the efficacy of GnRH-ant pro-
tocols with GnRH-a long protocol, it may be time to try
to close the debate. Recently, three meta-analysis have
been published with the aim to compare the GnRH-ant
regimens with the GnRH-a long protocol. The meta-
analysis by Al Inany [13] examines the first five com-
parative studies of fixed GnRH-ant protocol with the
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pregnancy rate (PR) per randomized woman was 0.78
(95% CI 0.62-0.97) in favour of agonist regimen, and the
absolute treatment effect was 5%, thus meaning that 5%
lower PR was observed with GnRH-ant regimen.
A second study by Kolibianakis et al., [39] is a meta-
analytic review of 22 RCTs published as full papers in
peer reviewed journals analysing a total of 3,100 patients.
The primary outcome was live birth. The study showed
that the probability of live birth between GnRH-ant and
GnRH-a was not significantly different (OR 0.86, 95% CI
0.72 to 1.02, P = 0.085), meaning that one could not
identify significant differences with respect to the prob-
ability of live birth independently of the population stud-
ied, type of gonadotropin used for stimulation, or type of
agonist protocol (fixed or flexible GnRH-ant regimen).
The third study is an additional updated meta-analysis
by Al Inany. This study showed that there was no sig-
nificant difference following GnRh ant compared with
GnRh agonist regimens (OR 0.86, 95% CI = 0.69 to 1.08,
P = 0.20)in the live birth rate and in the ongoing preg-
nancy rate per woman randomized (OR=0.88, 95% CI =
0.77 to 1.00, P = 0.05) .
Conclusions of meta analysis
Overall, these studies now demonstrate comparable efficacy
and better safety of GnRH ant protocol than GnRh agonist
protocol. Previous studies have shown a lower clinical and
ongoing pregnancy rates for the GnRh antagonist protocols.
In fact, these studies show some confounding variablesFigure 3 Linear regression analysis between patient’s age and numbe
antagonist group (B). In GnRH antagonist protocol it was observed a pos
luteo-follicular transition induces FSH levels above the treshold for a short-
follicular growth of a few leading follicle. After exogenous FSH administrati
additional follicles to grow, leading to a less synchronization of the follicula
antagonist protocol no correlation was observed between number of follic
above the threshold following pituitary downregulation and FSH exogenou
recruitment (Depalo et al., Gynecol Endocrinol. 2009) [45].from a methodological point of view: 1. data were pooled
from patients with previously failed IVF attempts; 2. basal
FSH, BMI, and duration of fertility were not stated; 3. three
type of antagonist protocol (single dose, flexible and fixed
administration protocols), 4. GnRH-a treatment by either
daily intranasal or subcutaneus administration, and 5. dif-
ferent starting dose of FSH were considered.
Moreover GnRH-ant were often used in cycles with an
unfavourable prior outcomes, i.e. patients with advanced
age and with a higher number of previously unfavour-
able cycles, thereby carrying a possible risk of introdu-
cing confounding factors.
As of now, we emphasize what has been suggested by
Griesinger, that, “Perhaps GnRH antagonist is used as
drug of second choice in IVF practice?” This Author,
evaluating the data from the Germany IVF registry and
stratifying the results by cycles rank, observed that the
proportion of GnRH-ant cycles increases from 23% in first
treatment to 35% in fifth treatment and to 48% in tenth
treatment. Engels et al., analyzing the data retrieved from
the National Germany IVF registry demonstrated that
GnRH-ant are comparatively more often employed in
higher ranks of treatment and that the proportion of older
women is comparatively higher in antagonist cycles. Thus,
they concluded that GnRH-ant are currently often used as
a second line medication or as first line treatment for pa-
tient with lower chances for pregnancy.
Sub-analysis of patients with equal demographic and
clinical features resulted in similar pregnancy rates inde-
pendent of whether GnRH agonist or antagonist was usedr of oocytes in the GnRH agonist group (A) and the GnRH
itive correlation between number of oocytes and patient’s age: the
period until hormonal feedback occurs, leading to the initiation of
on, FSH levels arise above threshold again and will initiate several
r cohort, and a more natural recruitment of follicles. In GnRH
les and patient’s age. In GnRH agonist protocol, FSH levels remain
s administration, resulting in a more synchronized follicular
Table 1 Advantages and disadvantages of GnRH agonist protocols and GnRH antagonist protocols
GnRH Agonist long GnRH Antagonist fixed GnRH Antagonist flexible GnRH agonist short and
ultra-short




FSH levels leading to a
follicular cohort of all small
follilcles at the initiation of





secretion which avoids effects
related to the initial flare up
and subsequent down
regulationB. Initiation of the
IVF treatment in a normal
menstrual cycleC.
Endogenous inter-cycle FSH
rise rather than FSH
suppression, thus resulting in
a significant reduction in the
effective dosage and shorter
treatment, than with GnRHa
A. Reduced dose of the
antagonist is neededB. The
cohort of follicles have more
time to develop thus leading
to a higher number of follicles
in mid-follicular phase
A.The ovarian suppression is
not excessiveB. The initial




effects of the exogenously
administered gonadotropins
Disadvantagess A. More time counsuming
and complex stimulation
protocolsB. Acute stimulation
of gonadotropins and steroid












unsuppressed during the early
follicular phase and enhance
E2 production










A. More IVF cycles to be
carried out in a given
periodB. Starting stimulation
in patient scheduled for
antineoplastic treatments
(oocyte cryopreservation)
It makes feasible to tailor
stimulation to patients’ needs
A. A microdose GnRHa flare
protocol is useful in poor
respondersB. Several
microdoses of GnRHa in the
flare up protocols have been
tested to achieve
gonadotropin release and
avoid side-effects of the
classic flare up protocol
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studies using GnRH-ant it seems, that the differences in
reported outcome measurements could be the conse-
quence of the large variation of population included in
the studies. In a RCT by our group, in which a strict in-
clusion criteria of patients was applied, it was shown
that Implantation rate, clinical Pregnancy rate and mis-
carriage rates were similar in the GnRH-antag regimens
as well in GnRH-a long protocol. However a signifi-
cantly higher number of oocytes and higher proportion
of mature MII oocytes was retrieved per patient rando-
mized, in the GnRH agonist group compared to the
GnRH ant group. Moreover a significantly relationship
was observed between patient’s age and number of
oocytes retrieved in antagonist group meaning that
GnRH antag allows a more natural recruitment of folli-
cles in the follicular phase in an ovary that has not been
suppressed, whereas a better synchronization of the fol-
licular cohort is observed in agonist treatment (Figure 3)
[45] (Table 1).
More recently, a retrospective cohort review of
first-time IVF cycles in good responders, has demon-
strated that clinical pregnancy rates and live birth
rates are similar utilizing either GnRh agonist or
GnRh antagonist [46].Conclusions
GnRH-ant regimen is effective in preventing a prema-
ture rise of LH and therefore results in a shorter and
more cost-effective ovarian stimulation protocol com-
pared to the long agonist protocol. However, there is dif-
ference in the synchronization of follicular recruitment
and growth in the GnRH-a and GnRH-ant regimens,
with better follicular growth and oocyte maturation seen
with GnRH-a treatment [45].
The effect of elevated LH levels in follicular phase be-
fore GnRH-ant administration, has to be focused on. An
optimization of the currently used stimulation protocol
is needed with regard to timing of GnRH-ant adminis-
tration, taking into account strategies for mild ovarian
stimulation, making more patient friendly IVF protocols
for patients who have to initiate radio-chemotherapy
procedures.
Finally, several aspects of the GnRH-ant use needs to
be further explored such as the direct effects of GnRH-
ant on extra-pituitary tissues (i.e., corpus luteum, endo-
metrium, ovary, embryo), and potential pharmacological
differences among the existing compounds.Competing interests
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